Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533031 | 0.85 | CYP1A2 (0.45) | BACE1CYP1A2CYP2A6PDE3BPDE3A | |
| SCHEMBL5535942 | 0.80 | NQO1 (0.43) | CYP1A2CA2CA12CA1CA7 | |
| SCHEMBL534326 | 0.77 | ALOX15 (0.34) | ALDH1A1CYP3A4MAPTMEN1KMT2A | |
| SCHEMBL5534581 | 0.77 | NPC1 (0.43) | CYP1A2CYP3A4MAPTKMT2ACLK1 | |
| SCHEMBL1474219 | 0.76 | ALDH1A1 (0.40) | CA2CA12CA1CA7CA9 | |
| SCHEMBL443070 | 0.71 | CYP1A2 (0.79) | CYP1A2CYP2A6CA2CA12CA1 | |
| SCHEMBL29447161 | 0.71 | CYP1A2 (0.79) | CYP1A2CYP2A6CA2CA12CA1 | |
| SCHEMBL533196 | 0.71 | AKR1C3 (0.32) | — | |
| SCHEMBL16289860 | 0.70 | MAPT (0.46) | CA2CA12CA1CA7CA9 | |
| SCHEMBL533343 | 0.70 | STING1 (0.38) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115716849-A | Synthetic method of aryl phosphorus compound | 海南大学 | 2023-02-28 | — | — | CN | claimed |
| EP-3510026-B1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-12 | — | — | EP | claimed |
| EP-3510026-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2019-07-17 | — | — | EP | claimed |
| US-10000473-B2 | Indazole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | claimed |
| WO-2018048762-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | WO | claimed |
| US-20180065955-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | claimed |
| WO-2003028725-A1 | 4-(1-PIPERIDINY)-BUTYLCARBOXAMIDE AS D3 DOPAMINE RECEPTOR SUBTYPE SELECTIVE LIGANDS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-04-10 | — | — | WO | claimed |
| US-5116986-A | HETEROAROMATIC AMINE DERIVATIVES | DR. KARL THOMAE GMBH (DE) | 1992-05-26 | — | — | US | claimed |
| US-4912115-A | Cardiovascular disorders | DR. KARL THOMAE GMBH (DE) | 1990-03-27 | — | — | US | claimed |
| CN-115716849-A | Synthetic method of aryl phosphorus compound | 海南大学 | 2023-02-28 | — | — | CN | disclosed |
| US-20200377462-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-03 | — | — | US | disclosed |
| US-10774048-B2 | Indazole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-15 | — | — | US | disclosed |
| EP-3510026-B1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3510028-B1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-05 | — | — | EP | disclosed |
| EP-1300405-A1 | AMINO ALCOHOL DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-09 | — | — | EP | disclosed |
| CN-1287117-A | Cyclobutene derivatives, preparation method and therapeutic use thereof | SANKYO CO (JP) | 2001-03-14 | — | — | CN | disclosed |
| EP-1070703-A1 | Cyclobutene derivatives | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-5175157-A | Cardiovascular disorders | BOEHRINGER INGELHEIM GMBH (DE) | 1992-12-29 | — | — | US | disclosed |
| US-5116986-A | HETEROAROMATIC AMINE DERIVATIVES | DR. KARL THOMAE GMBH (DE) | 1992-05-26 | — | — | US | disclosed |
| US-4912115-A | Cardiovascular disorders | DR. KARL THOMAE GMBH (DE) | 1990-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774048-B2 | Indazole derivatives useful as glucagon receptor antagonists | GPR119, GLP1R, GIPR | BACE1 2338/4885CYP1A2 296/4885CYP2A6 917/4885 |
| US-20200377462-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | BACE1 2338/4885CYP1A2 296/4885CYP2A6 917/4885 |
| US-20180065955-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | BACE1 2338/4885CYP1A2 296/4885CYP2A6 917/4885 |
| US-10000473-B2 | Indazole derivatives useful as glucagon receptor antagonists | GPR119, GLP1R, GIPR | BACE1 2338/4885CYP1A2 296/4885CYP2A6 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.